The fibrosis model offered by Umeå based company InfiCure is attracting international attention and last month the startup signed their first contract for a full-service preclinical pilot study to test two substances for an american client in Boston. The trial i currently underway, with all lab work beeing done on location in Umeå.
Late October, InfiCure Bio signed up for collaboration with their first ever international client – a life sciences company situated in Boston, USA. Currently, lab work is underway in Umeå to complete and deliver the first order abroad.
The order is for a full-service preclinical trial of two substances with potential to affect fibrosis – or scar tissue formation in organs due to long lasting inflammation. As there is a limited number of model systems available for fibrosis studies. The shortage of preclinical testing systems makes the whole organism-model offered by InfiCure Bio an attractive option.
Besides increasing Inficure’s credibility as a professional trail service partner, the international order gives the emplyees a well deserved boost in motivation. Sofia Mayans, CEO at InfiCure Bio, is please with the project so far.
The project is expected to take around a month to complete. If the substances perform well, further collaboration may be in stora – as this first order is a pilot study.
